Investment Opportunity in AI-Powered Patient Education

OP/AID is an AI-powered patient education platform addressing a widespread challenge in healthcare: patients often receive complex information during short consultations, retain only a limited part of it and lack reliable guidance throughout their treatment journey. At the same time, healthcare professionals spend valuable time repeatedly explaining standard information.

OP/AID provides structured, personalized patient education from preparation and prehabilitation through treatment to rehabilitation. The platform is built on a professionally reviewed and clinically validated medical content base, enabling healthcare providers to deliver reliable and consistent information rather than relying on uncontrolled, general-purpose AI-generated content.

The platform currently includes several hundred patient education texts covering multiple medical specialties. Medical and clinical validation is underway in cooperation with the University of Pécs Clinical Centre, while discussions and preparations involving additional healthcare institutions are progressing. OP/AID can save healthcare professionals approximately five minutes per consultation while improving patient understanding, engagement and continuity of information.

Our primary business model is based on granting country-specific licensing rights to selected partners capable of supporting the local implementation, adaptation and commercialisation of OP/AID. Through these licensing partnerships, the platform can be introduced to hospitals, surgical centres and healthcare networks while being adapted to local healthcare systems, languages, clinical workflows and regulatory requirements.

Following validation in Hungary, OP/AID is preparing for international market entry and strategic licensing partnerships across Europe and North America.

We are seeking pre-seed/seed investment and strategic investors with experience in digital health, healthcare technology, artificial intelligence or international B2B scaling. The investment would support further product development, the expansion of platform capabilities—including OP/AID’s own AI avatar—additional clinical and market validation, and international commercial growth.

We welcome discussions with investors who share our ambition to make trustworthy, personalized patient education a standard part of modern healthcare.